Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/278404 
Autor:innen: 
Erscheinungsjahr: 
2023
Schriftenreihe/Nr.: 
Research Paper No. 173
Verlag: 
South Centre, Geneva
Zusammenfassung: 
This paper provides an analysis of patents covering selected antibodies and vaccines used in the treatment or prevention of COVID-19. The aim of the report is to support national patent offices and interested parties in developing countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent applications. The antibody combination considered for the patent analysis in this paper are Casirivimab and Imdevimab. The vaccines considered for the patent analysis are mRNA-1273, Sputnik, ChAdOx1 nCoV-19 vaccine (AZD1222). The analysis was completed in May 2022.
Schlagwörter: 
Access to Medicines
Antibodies
COVID-19
Global Health
Health
Intellectual Property
Pandemic
Patent
Patent Examination
Patent Law
Patent Offices
Patent Policy
Patent Protection
Public Health
Vaccines
Dokumentart: 
Research Report
Erscheint in der Sammlung:

Datei(en):
Datei
Größe
4.78 MB





Publikationen in EconStor sind urheberrechtlich geschützt.